<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>BROOKS</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">BROOKS</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="brooks-laboratories-limited" class="section level1">
<h1>Brooks Laboratories Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BROOKS.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BROOKS.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BROOKS.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BROOKS.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BROOKS.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BROOKS.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BROOKS.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BROOKS.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.BROOKS.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-11-27 </em></p>
<div id="brooks-laboratories-limited-brooks-analysis" class="section level9">
<p class="heading">Brooks Laboratories Limited (BROOKS) Analysis</p>
<p><strong>Company Overview</strong>: Brooks Laboratories Ltd. is a pharma company engaged in manufacturing and trading of APIs, intermediates, and formulations. It operates two segments: Manufacturing (dominant, ~95% revenue) and Trading. Key JV: Brooks Steriscience Ltd. (sterile injectables). Listed on BSE/NSE. Data from Q2/H1 FY26 (ended Sep 30, 2025), AGM (Sep 26, 2025), and related disclosures.</p>
<div id="financial-snapshot-lakhs-consolidated-unless-stated" class="section level12">
<p class="heading"><strong>Financial Snapshot (₹ Lakhs, Consolidated unless stated)</strong></p>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>H1 FY26</th>
<th>H1 FY25</th>
<th>YoY Chg</th>
<th>FY25 (Audited)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue</strong> (Standalone)</td>
<td>4,896</td>
<td>3,873</td>
<td>+26%</td>
<td>8,256</td>
</tr>
<tr class="even">
<td><strong>PBT</strong> (Standalone)</td>
<td>489</td>
<td>74</td>
<td>+559%</td>
<td>323</td>
</tr>
<tr class="odd">
<td><strong>PBT</strong> (Consol., incl. JV share)</td>
<td>1,756</td>
<td>(638)</td>
<td>Turnaround</td>
<td>(637, FY25 H1 loss)</td>
</tr>
<tr class="even">
<td><strong>JV Profit Share</strong></td>
<td>1,287</td>
<td>(712)</td>
<td>Reversal</td>
<td>N/A</td>
</tr>
<tr class="odd">
<td><strong>EPS</strong> (Basic, Diluted)</td>
<td>5.96</td>
<td>(2.43)</td>
<td>Turnaround</td>
<td>N/A</td>
</tr>
<tr class="even">
<td><strong>Trade Receivables</strong></td>
<td>2,520</td>
<td>N/A</td>
<td>↑ from 1,999 (Mar25)</td>
<td>1,999</td>
</tr>
<tr class="odd">
<td><strong>Cash from Ops</strong></td>
<td>32</td>
<td>N/A</td>
<td>Modest</td>
<td>263 (FY25)</td>
</tr>
<tr class="even">
<td><strong>Equity Capital</strong></td>
<td>2,946</td>
<td>2,625</td>
<td>Stable post FY25 raise</td>
<td>2,946</td>
</tr>
</tbody>
</table>
<ul>
<li><strong>Key Driver</strong>: JV (Brooks Steriscience) revenue ₹6,782 (H1 FY26, incl. ₹3,913 licensing income), PAT ₹2,586 → Co.’s 50% share ₹1,287 (vs prior losses).</li>
<li><strong>Balance Sheet</strong>: Strong equity (₹11,567 cr consol.), high investments in JV (₹8,624). Low debt (borrowings ~₹645).</li>
<li><strong>Segments</strong>: Mfg. revenue H1 FY26: ₹4,652 (+26% YoY); Trading: ₹244 (+26% YoY).</li>
</ul>
</div>
<div id="tailwinds-positive-factors" class="section level12">
<p class="heading"><strong>Tailwinds (Positive Factors)</strong></p>
<ul>
<li><strong>Revenue Momentum</strong>: Standalone +26% YoY; Q2 FY26 +13% YoY despite Q1-Q2 dip (seasonal?).</li>
<li><strong>Profitability Turnaround</strong>: From losses to ₹1,756 PBT consol. (JV licensing/tech transfer boost).</li>
<li><strong>JV Synergies</strong>: Steriscience’s sterile injectables + licensing success signals commercialization potential.</li>
<li><strong>Capital Infusion</strong>: FY25 preferential issue (₹4,250 proceeds) bolstered equity; low debt aids flexibility.</li>
<li><strong>Segment Balance</strong>: Mfg. stable; Trading turnaround (Q2 profit ₹31 vs Q1 loss).</li>
<li><strong>Cash Position</strong>: Ops cash positive; low finance costs (↓ YoY).</li>
</ul>
</div>
<div id="headwinds-challenges" class="section level12">
<p class="heading"><strong>Headwinds (Challenges)</strong></p>
<ul>
<li><strong>Quarterly Slowdown</strong>: Q2 standalone revenue -8% QoQ (₹2,345 vs ₹2,551); expenses sticky (materials +ve inventory change).</li>
<li><strong>JV Dependency</strong>: ~73% consol. PBT from JV; licensing income (58% of JV revenue) may not recur.</li>
<li><strong>Working Capital Strain</strong>: Receivables ↑26% QoQ; inventories ↓ but payables ↓ (net WC drag).</li>
<li><strong>Shareholder Dissent at AGM</strong>: | Resolution | Public Non-Inst. Against % | Passed? | |————|—————————-|———| | RPT Approval | 35% | Yes (83% overall) | | Restructuring (Merger/Demerger) | 41% | Yes (89%) | | MoA Alteration | 93% | Yes (75%) |
<ul>
<li>Signals governance concerns; promoters/public split evident.</li>
</ul></li>
<li><strong>No DTA Recognition</strong>: Business losses/depreciation → tax shield deferred (Ind AS 12).</li>
</ul>
</div>
<div id="growth-prospects" class="section level12">
<p class="heading"><strong>Growth Prospects</strong></p>
<ul>
<li><strong>High (Medium-Term)</strong>:
<ul>
<li><strong>Pharma Tailwinds</strong>: India API/export growth; sterile injectables demand (JV focus).</li>
<li><strong>JV Upside</strong>: Licensing ₹3,913 (H1) hints at tech/IP monetization; potential full integration post-AGM restructuring nod (sale/merger/demerger of JV stake).</li>
<li><strong>Restructuring Flexibility</strong>: AGM approvals (Res 6-8) enable slump sale/amalgamation → value unlock (e.g., JV investment ₹8,624 disposal).</li>
<li><strong>Organic</strong>: Revenue trajectory +26% YoY; capex (CWIP ₹92) for expansion.</li>
<li><strong>Projections</strong>: If JV licensing sustains/recurs + standalone margins hold (10-11% PBT), FY26 consol. revenue &gt;₹18,000; EPS &gt;₹12 (analyst-like view).</li>
</ul></li>
<li><strong>Catalysts</strong>: Q3 results (Dec 2025); JV updates; restructuring execution.</li>
</ul>
</div>
<div id="key-risks" class="section level12">
<p class="heading"><strong>Key Risks</strong></p>
<table>
<colgroup>
<col width="44%" />
<col width="26%" />
<col width="29%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Details</th>
<th>Severity</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>JV Concentration</strong></td>
<td>73% profit reliance; licensing non-recurring? JV audited separately.</td>
<td><strong>High</strong></td>
</tr>
<tr class="even">
<td><strong>Governance/RPT</strong></td>
<td>AGM dissent (35-93% public against); promoter-related RPT scrutiny.</td>
<td><strong>High</strong></td>
</tr>
<tr class="odd">
<td><strong>Liquidity/DSO</strong></td>
<td>Receivables 90+ days?; Ops cash modest (₹32 H1).</td>
<td><strong>Medium</strong></td>
</tr>
<tr class="even">
<td><strong>Operational</strong></td>
<td>Raw mat. volatility (27% expenses); forex (unrealized gains noted).</td>
<td><strong>Medium</strong></td>
</tr>
<tr class="odd">
<td><strong>Regulatory</strong></td>
<td>SEBI scrutiny post-AGM; pharma pricing/approvals.</td>
<td><strong>Medium</strong></td>
</tr>
<tr class="even">
<td><strong>Market</strong></td>
<td>Competition (API generics); no institutional holding (0% in AGM).</td>
<td><strong>Low-Medium</strong></td>
</tr>
<tr class="odd">
<td><strong>Macro</strong></td>
<td>Pharma export curbs? Himachal (Baddi plant) incentives.</td>
<td><strong>Low</strong></td>
</tr>
</tbody>
</table>
<p><strong>Overall Summary</strong>: <strong>Bullish with Caution</strong>. Strong H1 turnaround (JV-driven) + revenue growth outweigh near-term dips, positioning for 20-30% FY26 growth. Tailwinds from JV/IP and restructuring approvals strong; headwinds (governance, WC) manageable but monitor Q3. <strong>Investment Thesis</strong>: Buy on dips if JV proves sustainable; target 20-25% upside (P/E ~15x FY26 EPS). Risks tilted to JV/governance – watch RPT disclosures &amp; shareholder actions. Data as of Nov 2025 filings.</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
